(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 January 2005 (27.01.2005)

PCT

(10) International Publication Number
WO 2005/007143 A2

(51) International Patent Classification[7]: A61K 31/00

(21) International Application Number: PCT/US2004/022406

(22) International Filing Date: 12 July 2004 (12.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/486,979 14 July 2003 (14.07.2003) US

(71) Applicant *(for all designated States except US)*: **THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS** [US/US]; 352 Administration Building, 506 South Wright Street, Urbana, IL 61801 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **FALZARI, Kanakeshware** [IT/US]; 229 Marengo Avenue, #502, Forest Park, IL 60131 (US). **FRANZBLAU, Scott, G.** [US/US]; 863 North Winthrop Avenue, #3, Chicago, IL 60660 (US). **ZHU, Zhaohai** [CN/US]; 33955 Treeline Court, Grayslake, IL 60030 (US).

(74) Agent: **NAPOLI, James, J.**; Marshall, Gerstein & Borun LLP, 233 S. Wacker Drive, Suite 6300, Sears Tower, Chicago, IL 60606-6357 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2005/007143 A2

(54) Title: METHOD OF TREATING TUBERCULOSIS

(57) Abstract: Macrolide and ketolides, and compositions containing the same, useful in the treatment of tuberculosis are disclosed. Methods of treating tuberculosis using the macrolides and ketolides, and compositions containing the same, also are disclosed.

METHOD OF TREATING TUBERCULOSIS

CROSS REFERENCE TO RELATED APPLICATION

This application claims the benefit of U.S. provisional patent application Serial No. 60/486,979, filed July 14, 2003.

FIELD OF THE INVENTION

The present invention relates to methods of treating tuberculosis. More particularly, the present invention relates to a method of treating tuberculosis comprising administrating a therapeutically effective amount of a macrolide, a ketolide, or mixtures thereof, or a composition containing a macrolide, a ketolide, or mixtures thereof, to an individual in need thereof.

BACKGROUND OF THE INVENTION

Tuberculosis (TB) is an infectious disease that usually attacks the lungs, but is capable of attacking most parts of the body. Tuberculosis is spread from person to person through the air. When individuals infected with TB cough, laugh, sneeze, sing, or talk, TB bacteria can be spread into the air. If a second person inhales TB bacteria, a possibility exists that the second person also will become infected with tuberculosis. However, repeated contact typically is required for infection.

Medical experts estimate that about 10 million Americans are infected with TB bacteria, and

about 10 percent of these people will develop active TB in their lifetime. However, TB is an increasing worldwide problem, especially in Africa. It is estimated that, worldwide, about one billion people will become newly infected, over 150 million people will contract active TB, and 36 million people will die between now and 2020 unless TB control is improved.

An individual infected with TB, but not suffering from TB disease, i.e., has latent TB, can be administered preventive therapy. Preventive therapy kills bacteria in order to prevent a case of active TB. The usual treatment for latent TB is a daily dose of isoniazid (also termed "INH").

If an individual has TB disease, i.e., has active TB, the individual typically is administered a combination of several drugs. It is very important, however, that the individual continue a correct treatment regimen for the full length of the treatment. If the drugs are taken incorrectly, or stopped, the individual can suffer a relapse and will be able to infect others with TB.

When an individual becomes sick with TB a second time, the TB infection may be more difficult to treat because the TB bacteria have become drug resistant, i.e., TB bacteria in the body are unaffected by some drugs used to treat TB. Multidrug-resistant tuberculosis (MDR TB) is a very dangerous form of tuberculosis. In particular, some TB bacteria become resistant to the effects of various anti-TB drugs, and these resistant TB bacteria then

can cause TB disease. Like regular TB, MDR TB can be spread to others.

To avoid drug resistance in the treatment of TB, a four-drug regimen, i.e., isoniazid, rifampin, pyrazinamide, and streptomycin, is administered to TB patients. Aminoglycosides, such as streptomycin, are important anti-TB agents, but their utility is restricted by the requirement of parenteral administration, which is inconvenient and leads to poor patient compliance. It is theorized that poor patient compliance also can lead to the development of drug resistance, and it appears that the frequency of streptomycin resistance among anti-TB drugs is surpassed only by isoniazid.

In view of the above, an urgent need exists for new anti-TB agents useful in an effective treatment regimen for both the active and latent TB, and that effectively treat TB caused by multidrug resistant (MDR) strains of bacteria. Therefore, it would be advantageous to provide compounds and compositions for administration to an individual in the treatment of tuberculosis. As set forth in detail hereafter, the present invention is directed to the use of macrolide and ketolide compounds, and pharmaceutical compositions containing the same, useful in methods of treating tuberculosis.

SUMMARY OF THE INVENTION

The present invention is directed to a method of treating tuberculosis (TB). More particularly, the present invention is directed to a

method of treating latent, active, and multidrug-resistant TB by administering a therapeutically effective amount of a macrolide, a ketolide, or mixtures thereof, to a mammal in need thereof.

Accordingly, one aspect of the present invention is to provide a method of treating TB in a mammal, including humans.

Another aspect of the present invention is to provide a pharmaceutical composition comprising a macrolide, ketolide, or mixtures thereof that can be administered to an individual in a therapeutically effective amount to treat latent, active, or multi-drug-resistant TB. In preferred embodiments, the macrolide or ketolide has an MIC vs. *M. tuberculosis* of about 50 μM or less, e.g., about 0.01 nM to about 50 μM.

Another aspect of the present invention is to provide a method of treating TB comprising administering to a mammal in need thereof (a) a pharmaceutical composition comprising a macrolide, a ketolide, or mixtures thereof and, optionally, (b) one or more additional drugs useful in the treatment of TB.

Still another aspect of the present invention is to provide an article of manufacture comprising:

(a) a packaged pharmaceutical composition comprising a macrolide, a ketolide, or mixtures thereof;

(b) an insert providing instructions for the administration of the macrolide, ketolide, or mixture thereof to treat TB; and

(c) a container for (a) and (b).

Yet another aspect of the present invention is to provide an article of manufacture comprising

(a) a packaged composition comprising a macrolide, a ketolide, or mixtures thereof;

(b) a packaged composition comprising a second therapeutic agent useful in a treatment of tuberculosis;

(c) an insert providing instructions for a simultaneous or sequential administration of (a) and (b) to treat tuberculosis; and

(d) a container for (a), (b), and (c).

These and other aspects and advantages of the present invention will become apparent from the following detailed description of the preferred embodiments.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The macrolide classes of clinically useful antimicrobial agents fail to include tuberculosis as a treatable indication. Consequently, macrolides and ketolides, including derivatives of known macrolides and ketolides, were investigated for the possibility of providing a clinically useful anti-TB drug.

Erythromycin and related macrolide antibiotics are among the safest and most effective treat-


ments for diseases caused by *Streptococci* and *Staphylococci* bacteria. Although some of these antibiotics are active against some related mycobacteria, such as those that cause leprosy, other skin infections, and opportunistic infections in HIV/AIDS, these antibiotic are not clinically useful for the treatment of tuberculosis. The newest macrolides, designed to overcome resistance of *Staph* and *Strep*, are not themselves active against *M. tuberculosis*, but it now has been found that related compounds possess potent anti-TB activity.

Although previous macrolides have not shown potent anti-TB activity, the macrolides as a class are attractive compounds for treating TB because of the following properties: (a) excellent oral bioavailability and distribution to the lungs, (b) low toxicity, (c) infrequent adverse reactions, (d) extensive intracellular concentration and activity, and (e) a demonstrated clinical utility and bactericidal activity in infections caused by *M. avium* and *M. leprae*. In addition, erythromycin is a relatively inexpensive starting material for the preparation of new anti-TB macrolides, and a majority of the synthetic routes are relatively short, e.g., typically 10 steps or less. Thus, a new anti-TB drug arising from this class of compounds is considered to be economically viable.


Erythromycin, a prototypical first generation macrolide, is a natural product derived from *Streptomyces erythreus*. Erythromycin interferes with protein synthesis on the 50S subunit of 70S

ribosomes by binding in the peptidyl transferase center and blocking the movement of proteins through the exit tunnel. Erythromycin originally was used as an alternative agent in the treatment of patients with infections caused by *Staphylococcus* and *Streptococcus* species, but who were allergic to β-lactams. Erythromcyin possesses most of the favorable macrolide properties mentioned above, but suffers from a short serum half-life, thus necessitating tid or qid dosing (i.e., three or four times per day, respectively), and acid lability, the product of which leads to gastric motility-based discomfort. In addition, erythromycin activity is restricted to controlling Gram positive bacteria.

Second generation macrolides were developed to have superior acid stability and serum half-life. Clarithromycin, roxithromycin, and azithromycin are examples of such second generation macrolides.



R_6, R_9 = H,O: Erythromycin
R_6, R_9 = Me,O: Clarithromycin
R_6, R_9 = H, $NOCH_2O(CH_2)_2OMe$: Roxithromycin



Azithromycin

When the second generation macrolides entered phase II and III trials for infections caused by Gram positive and Gram negative pathogens, *M. avium* was becoming recognized as a significant pathogen in HIV-infected individuals, and *in vitro*

metabolic assays were being developed for the unculturable *M. leprae*, which facilitated the search for new bactericidal drugs to shorten the treatment duration. It became apparent that the second generation macrolides, i.e., clarithromycin and azithromycin, along with rifabutin, were the most active clinical agents against *M. avium* (G.W. Amsden et al., *Drugs*, *54*:69-80 (1997)).

With the exception of azithromycin, these compounds also were found to possess potent activity against *M. leprae* in axenic media (S.G. Franzblau, *Antimicrob Agents Chemother*, *33*:2115-7 (1989); S.G. Franzblau et al., *Antimicrob Agents Chemother*, *32*:1758-62 (1988)), in macrophages (N. Ramasesh et al., *Antimicrob Agents Chemother*, *33*:657-62 (1989)), mice (S.G. Franzblau et al., *Antimicrob Agents Chemother*, *32*:1758-62 (1988); B. Ji et al., *Antimicrob Agents Chemother*, *40*:393-9 (1996)), and ultimately in clinical trials (G.P. Chan et al., *Antimicrob Agents Chemother*, *38*:515-7 (1994); B. Ji et al., *Antimicrob Agents Chemother*, *40*:2137-41 (1996); T.H. Rea, *Int J Lepr Other Mycobact Dis*, *68*:129-35 (2000)). Clarithromycin currently is recommended by the World Health Organization for treatment of leprosy in cases of rifampin resistance or intolerance (J.H. Grosset, *Int J Lepr Other Mycobact Dis*, *69*:S14-8 (2001)). Other studies demonstrated low MICs (minimum inhibitory concentrations) and/or a clinical utility of second generation macrolides against *M. kansasii* (R.S. Witzig et al., *Antimicrob Agents Chemother*, *37*:1997-9 (1993)), *M.*


marinum (A. Aubry et al., *Arch Intern Med, 162*:1746-52 (2002); A. Aubry et al., *Antimicrob Agents Chemother, 44*:3133-6 (2000); M. Braback et al., *Antimicrob Agents Chemother, 46*:1114-6 (2002); B.A. Brown et al., *Antimicrob Agents Chemother, 36*:1987-90 (1992)), and other mycobacterial opportunistic pathogens (B.A. Brown et al., *Antimicrob Agents Chemother, 36*:1987-90 (1992); N. Rastogi et al., *Antimicrob Agents Chemother, 36*:2841-2 (1992)).

The impressive activity of second generation macrolides did not include an activity against *M. tuberculosis*. The MIC of clarithromycin against the tubercle bacillus ranges from 4-64 µg/ml, and activity in mouse models was marginal (J. Luna-Herrera et al., *Antimicrob Agents Chemother, 39*:2692-5 (1995)) to nil (C. Truffot-Pernot et al., *Antimicrob Agents Chemother, 39*:2827-8 (1995)). Indeed the marginal activity reported by Luna-Herrera et al. (1995) is attributed to excellent distribution to the lungs and intracellular concentration. This study, together with a demonstrated activity in leprosy and *M. avium* infection, formed the basis for its anecdotal use in treating MDR-TB when therapeutic options are extremely limited (C. Mitnick et al., *N Engl J Med, 348*:119-28 (2003)). Clearly, *in vitro* and *in vivo* results indicate that clarithromycin cannot be expected to offer significant clinical benefits in the treatment of tuberculosis.


The innate resistance of *M. tuberculosis* to clarithromycin apparently is attributed to the

same resistance factors encountered in *Staph* and *Strep*, e.g., methylation of A2058 by a ribosome methylase (Rv1988) and possibly efflux (Rv0037c). The existence of an erythromycin esterase (Rv2030c) also could be a factor. *M. bovis* BCG and *M. leprae* are highly susceptible to clarithromycin, and each lack and each homologous genes.

The third generation of macrolides (J.M. Blondeau, *Expert Opin Pharmacother, 3*:1131-51 (2002); J.M. Blondeau et al., *Expert Opin Investig Drugs, 11*:189-215 (2002); G.G. Zhanel et al., *Expert Opin Pharmacother, 3*:277-97 (2002); G.G. Zhanel et al., *Drugs, 62*:1771-804 (2002)) are represented largely by the ketolides, and were developed with the intention of overcoming the ribosome modification and efflux resistance mechanisms found in Gram positive cocci. The 3-cladinose was hydrolyzed and the resulting 3-hydroxyl group was oxidized to a 3-carbonyl group. Structures of representative ketolides are:



Telithromycin



Cethromycin


Telithromycin was the first commercial third generation macrolide. Removal of the cladinose precludes active efflux, while the 11,12-carbamate substitution both precludes inducible ribosome modification and increases binding affinity in the peptidyl transfer site of the ribosome in the case of constitutively methylated ribosomes. The ketolide, cethromycin (ABT-773), used a 6-position substitution to overcome ribosome modification.

A comparative study of the antimycobacterial activity of clarithromycin vs. telithromycin (as well as the fluorinated analog of telithromycin, HMR or RU 3004) revealed a superior activity of clarithromycin for the moderately clarithromycin-susceptible mycobacteria *M. bovis* BCG, *M. avium*, *M. ulcerans*, and *M. paratuberculosis*, the clarithromycin-resistant mycobacteria *M. tuberculosis*, *M. bovis*, *M. africanum*, and *M. simiae* (N. Rastogi et al., *Antimicrob Agents Chemother*, *44*:2848-52 (2000)).


The present invention is directed to a method of treating tuberculosis utilizing a macrolide, a ketolide, or mixtures thereof. The macrolide, ketolide, or mixtures thereof can be used neat, or incorporated into a pharmaceutical preparation. The present method can utilize a single macrolide, a mixture of macrolides, a single ketolide, a mixture of ketolides, or a mixture of a macrolide and a ketolide.

Useful macrolides are disclosed herein and, for example, in U.S. Patent Nos. 5,439,889;

5,786,339; 5,543,400; and 6,096,714; and in WO 02/32919, each incorporated herein by reference. More particularly, in one embodiment, the macrolide comprises a compound disclosed in U.S. Patent No. 5,543,400, having a structural formula:




wherein R is




m and n are individually integers from 0 to 6, A and B are individually a member selected from the group consisting of hydrogen, halogen, and alkyl of 1 to 8 carbon atoms, the double bond geometry being E or Z or E+Z or A and B for a third bond between the carbon atoms to which they are attached, Ar is selected from the group consisting of a) carbocyclic aryl or up to 18 carbon atoms optionally substituted with at

least one member of the group consisting of free carboxy, alkoxycarbonyl, carboxy salified with a nontoxic, pharmaceutically acceptable base, amidified carboxy, -OH, halogen, $-NO_2$, -CN, alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, alkynyloxy, alkylthio, alkenylthio, and alkynylthio of up to 12 carbon atoms, N-alkyl, N-alkenyl, and N-alkynyl of up to 12 carbon atoms and cycloalkyl of 3 to 12 carbon atoms, all optionally substituted with at least one halogen and



R_1 and R_2 are individually selected from the group consisting of hydrogen, alkyl of 1 to 12 carbon atoms, carbocyclic aryl, aryloxy, arylthio, heterocyclic aryl, and aryloxy and arylthio containing at least one heteroatom, all optionally substituted as above and b) heterocyclic aryl having at least one heteroatom optionally substituted with at least one of the above substituents, Z is hydrogen or acyl or an organic carboxylic acid of 1 to 18 carbon atoms and their nontoxic, pharmaceutically acceptable acid addition salts.

In another embodiment, the macrolide comprises a compound disclosed in WO 02/32919, having a structural formula:



or a therapeutically acceptable salt or prodrug thereof, wherein

X is selected from hydrogen and fluoride;


D^1 is selected from CH=CH or C≡C;

Y^1 is selected from isoxazole, oxazole, isothiazole, dihydroisoxazole, and dihydrooxazole;


A^1 is selected from aryl and heteroaryl; and

R^1 is selected from hydrogen and R^p, wherein R^p is a hydroxyl protecting group.

In a third embodiment the macrolide comprises a compound disclosed in U.S. Patent No. 5,786,339 having a structural formula:




wherein R and R_1 are -OH or -O-acyl of an organic carboxylic acid of 2 to 20 carbon atoms, R_2 is hydrogen or methyl, R_3 is $-(CH_2)_m-R_4$ or



or $-N-(CH_2)_q-R_4$, m is an integer from 1 to 6, a, p, and q are individually an integer from 0 to 6, A and B are individually selected from the group consisting of hydrogen, halogen, and alkyl of 1 to 8 carbon atoms with the geometry of the double bond being E or Z or a mixture of E and Z or A and B form a triple bond, R_4 is an optionally substituted mono- or polycyclic heterocycle and their nontoxic, pharmaceutically acceptable acid addition salts.


In a further embodiment, the macrolide comprises a compound disclosed in U.S. Patent No. 6,096,714 having a structural formula:



wherein X represents a CH_2 or SO_2 radical or an oxygen atom, Y represents a $(CH_2)_m(CH=CH)_n(CH_2)_o$ radical, with $m+n+o \leq 8$, n=0 or 1,

Ar represents an optionally substituted aryl radical,


W represents a hydrogen atom, or the remainder of a carbamate function



wherein R" represents an alkyl radical containing up to 8 carbon atoms or an optionally substituted aryl radical, and


Z represents a hydrogen atom or the remainder of an acid, as well as their addition salts with acids.

In a fifth embodiment, the macrolide comprises a compound disclosed in U.S. Patent No. 5,439,889 having a structural formula:




,

wherein X and Y are hydrogen or together form



,


R is



,

m is an integer from 0 to 20, n is 0, 1, 2, or 3, A and B are individually selected from the group consisting of hydrogen, halogen, alkyl of 1 to 8 carbon atoms and aryl of 6 to 8 carbon atoms with the double bond geometry being E or Z or a mixture of E and Z or A and B form a third bond between the carbons to which they are attached, X_A is selected from the group consisting of alkyl, alkenyl, and alkynyl

of 6 to 20 carbon atoms optionally interrupted with at least one heteroatom and optionally substituted with at least one halogen, cycloalkyl of 3 to 8 carbon atoms optionally substituted by a carbocyclic aryl, halogen, -CN, $-OR_3$, $-COR_4$, $-COOR_5$, $-SR_6$, $-SOR_7$, $-SO_2R_8$,




$-OC(Ar)_3$, and a carbocyclic aryl and heterocyclic aryl optionally substituted, R_3, R_4, R_5, R_6, R_7, R_8, and R_9 are individually selected from the group consisting of hydrogen, alkyl of 1 to 8 carbon atoms optionally interrupted by at least one heteroatom and optionally substituted by at least one halogen, carbocyclic, and heterocyclic aryl and aralkyl of up to 14 carbon atoms optionally substituted with at least one member of the group consisting of free, salified, esterified, or amidified carboxy, -OH, halogen, $-NO_2$, -CN, alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, alkynyloxy, alkylthio, alkenylthio, alkynylthio, -SO-alkyl, -SO-alkenyl, -SO-alkynyl, $-SO_2$-alkyl, $-SO_2$alkenyl, and $-S_2$-alkynyl of up to 12 carbon atoms, all optionally substituted with at least one halogen, carbocyclic, and heterocyclic, aryl, O-aryl, and -S-aryl of up to 14 carbon atoms, R'_1 and R'_2 are individually selected from the group consisting of hydrogen and alkyl of 1 to 12 carbon atoms, R_1 and R_2 are individually selected from the

group consisting of hydrogen, alkyl of 1 to 20 carbon atoms, -COAlk, and -COO-Alk, aryl, -CO-aryl, -COO-aryl, aralkyl, -CO-aralkyl, and -COO-aralkyl of up to 14 carbon atoms, Alk of alkyl of 1 to 8 carbon atoms, or R_1 and R_2 together with the nitrogen to which they are attached form ring of 3 to 8 members optionally containing a second heteroatom and optionally substituted with the above aryl substituents, Ar is a carbocyclic aryl optionally substituted with at least one of the above aryl substituents, Z is hydrogen or aryl of an organic carboxylic acid of up to 18 carbon atoms and their nontoxic, pharmaceutically acid addition salts.


In addition to the above compounds, additional macrolides and ketolides having an activity against TB were synthesized. The important factors considered when designing the present anti-TB macrolides and ketolides were: 1) structural optimization for potency of 14-membered macrolides, including modifications at the 6-, 9-, and 11-positions on the macrolactone, while avoiding toxic functionalities, and 2) potent anti-TB activity in order to shorten duration of the TB chemotherapy regimen.

Preliminary results showed that 3-cladinose-containing macrolides demonstrate a more potent anti-TB activity than their counterpart ketolides by one to two orders of magnitude. For example, a 4-[4-(3-pyridinyl)-1H-imidazol-1-yl]butyl group (1) substituent at the nitrogen atom in 11,12-carbamate of telithromycin and in RU69874, and the

3-(4-quinolinyl)propyl group (2) at 11,12-carbazate of RU66252 provided potent anti-TB drugs.



1




2


This and other discoveries led to a synthesis of 3-cladinose-containing macrolides of the corresponding ketolides having potent anti-Gram positive bacterial activities. Scale-up of the synthetic schemes set forth in Schemes 1-4 was performed for an *in vivo* study. The third step of the reaction sequences, i.e., the Michael addition in Scheme 1 and Eschweiler-Clarke-type reaction in Scheme 2, illustrate of points for facile diversification of molecular structure.

The following four macrolides were prepared, the syntheses of which are disclosed hereafter. Each compound, i.e., RU60887, RU66252, RU69874, and A323348, exhibited a very low minimum inhibitory concentration (MIC) vs. *M. tuberculosis*. In follow-up assays, RU66252 demonstrated an MIC vs. *M. tuberculosis* of about 9 μM, which is still an excellent MIC, and RU66252 also is active against *M.*


tuberculosis in mice. In particular, RU66252 shows a dose response between 50 and 200 mg/kg in mice, with significant *M. tuberculosis* inhibition at 150 mg/kg and 200 mg/kg.




RU60887
MIC, μM: 0.12



RU66252
MIC, μM: 0.25




RU69874
MIC, μM: 0.38




A323348
MIC, μM: 0.38

Scheme 1. 11,12-Carbamate RU69874 Synthesis




3 (Clarithromycin)




1) $NaN(SiMe_3)_2$/THF, -40C

2) CDI/THF/DMF


4



5





6




7 (RU69874)

Scheme 1a. RNH_2 Synthesis







As discussed above, the four 11,12-carbamate ketolides, RU60856, RU62041, RU61143 and RU70332, demonstrated single digit MIC anti-TB activity with low toxicity in an *in vitro* study. Other amines that provide potent 11,12-carbamate anti-TB agents include: 4-(quinolinyl)butylamine (8), benzyloxyethylamine (9), 4-(3-chlorophenyl)-butylamine (10), 4-(8-methoxyquinolinyl)butylamine (11), 4-(6-methoxyquinolinyl)butylamine (12), 3-(aminophenyl)propylamine (13), 4-phenylbutylamine (14), and similar amines (15-25a).




8




9




10




11




12




13




14




15




16




17




18




19




20




21




22




23



24





25




25a

Scheme 2. 11,12-Carbazate RU66252 Synthesis









RU66252


Scheme 2a. RCHO Synthesis:




Following a synthetic route similar to Scheme 2, additional aldehydes can be used in the Eschweiler-Clarke-type reaction for parallel syntheses, including 3-(8-methoxyquinolinyl)propanal (26), 3-(6-methoxyquinolinyl)propanal (27), 3-(3-chorophenyl)propanal (28), benzenepropanal (29), and similar aldehydes, as set forth below.




26




27





28





29













5

The carbazate analogue of RU69874 also can be synthesized by reacting compound 123 with compound 37, as set forth in Scheme 3.


Scheme 3. Synthesis of Additional 11,12-Carbazates



123




38




39

Scheme 3a. Synthesis of Aryl Propyl Bromide




37


Additional aromatic heterocyles can be used for the syntheses shown in Scheme 3a.




30




31




32




33



34



35




36


Oximes

Analogous to the synthesis of 9-oxime ketolides (C. Agouridas et al., *J. Med. Chem.*, *41*:4080-4100 (1998)), 3-cladinose counterparts can be synthesized, as shown in Scheme 4. The synthetic route is shorter than ketolide synthesis because hydrolysis, protection, oxidation, and deprotection reactions can be omitted, while an improved opportunity to generate potent anti-TB compounds exists. The synthesis begins by coupling clarithromycin with a CBz protected hydroxylamine (Scheme 4a), followed by deprotection (41), and derivatization of the piperidine to the final 9-oxime 42.


Scheme 4. Synthesis of 3-Cladinose Analog of RU60887




3 (Clarithromycin)



40



NH
N
O
HO
OH
O
HO
N
O
O
O
O
OCH3
O
OH
Me(CH2)8CHO
H2, Pd/C
EtOH, AcOH

41


N
O
N
HO
OH
O
HO
N
O
O
O
O
OCH3
O
OH


42

Scheme 4a. Synthesis of Intermediate 43




43


Additional aldehydes useful in the last step of Scheme 4 include, but are not limited to, 3-(4-hydroxyphenyl)propanal (44), 3-cyclohexylpropanal (45), formaldehyde (46), benzenepropanal (29).



44



44a



45


HCHO

46

Additional hydroxylamines for use in the first step of Scheme 4 include, but are not limited to, hydroxylamine (47), ((2,4,6-trimethylphenyl)-methyl)hydroxylamine (48), (2-(dimethylamino)ethyl)-hydroxylamine (49). The hydroxylamines are used in their corresponding hydrochloride salt form. Only the first step in Scheme 4 is required to synthesize these 9-oximes

H_2NOH

47




48


$Me_2NCH_2CH_2ONH_2$

49

Scheme 5. Synthesis of Additional 9-Oximes



3 (Clarithromycin)




Amines useful for the final step of Scheme 5 include, but are not limited to, propylamine, 2-propynylamine (50), azetidine (51), 2-(1-pyrrolidinyl)ethylamine (52), and 3-(1H-imidazol-1-yl)-propylamine (53).

$HC{\equiv}C\text{-}CH_2NH_2$


50



51



52




53


6-*O*-Functionalized 11,12-Carbamates

The synthesis of 6-*O*-aryl allyl carbamates begins with TMS (trimethylsilyl) protection on the 4" and 2' hydroxyl groups 55, followed by allylation of 55 to 56 (Z. Ma et al., *J. Med. Chem.*, *44*:4137-4156 (2001)). Treatment of 56 with NaHMDS and carbonyldiimidazole generates 57, followed by cyclization to carbamate 58. Heck coupling, followed by deprotection with TBAF, lead to final product 60.


Scheme 6. Synthesis of 6-O-Aryl Carbamates




54 (Erythromycin)




55


HO
OH
O
TMSO
N
O
O
O
O
O
O
O
OTMS
CDI, NaHMDS
THF-DMF


56


N
N
O
O
O
TMSO
N
O
O
O
O
O
O
OTMS
NH4OH
CH3CN-THF


57


TMSO
NH
OH
N
N
Br
Pd(OAc)2, P(o-tolyl)3
Et3N, MeCN
OTMS

58



N
TMSO
NH
OH
N
OTMS

59




60


Additional aryl halides for use in the Heck coupling reaction include, but are not limited to, 5-bromothieno[2,3b]pyridine (61), 7-bromoquinoline (62), 6-chloroquinoline (63), 3-bromo-1,8-naphthyridine (64), 3-bromo-1,6-naphthyridine (65), 3-bromo-1,5-naphthyridine (66), and 6-bromocinnoline (67).




61




62




63




64



65



66




67


Scheme 7 illustrates a synthesis 6-*O*-aryl propargyl carbamates similar to the 6-*O*-aryl allyl carbamate in Scheme 6. The sythesis begins by propargylation of 155 (R.F. Clark et al., *Bioorg. Med. Chem. Lett.*, *10*:815-19 (2000)), followed by treatment with CDI. The acyl imidazole 154 is

cyclized to carbamate 155, and subsequently coupled with an aryl halide (Scheme 7a) (L.T. Phan et al., *Org. Lett., 2*:2951-2954 (2000)). Deprotection provides the final product 157.


Scheme 7. Synthesis of 6-*O*-Aryl Propargyl Carbamate




140




153


TMSO
OCH3
OTMS
NH4OH
CH3CN-THF


154


TMSO
OCH3
OTMS
(Ph3P)2PdCl2, CuI
Et3N, CH3CN, 80°C

155




156





157


Scheme 7a. Synthesis of the Substituent.





An additional aryl halides for use in Scheme 7 include, but are not limited to:



















5



















Azalides

Azalide analogues of the most active clarithromycin analogues, e.g., A323348, also can be synthesized. The synthesis begins with protection on reactive hydroxyl groups of azithromycin 158 to the protected form 159, which in turn couples with allyl bromide to 160. Heck coupling of 160 with the quinoline provides 161. TBAF deprotection provides to final product 162.


Scheme 8. Synthesis of 6-*O*-Quinolinyl Allyl Azalide




158




159


TMSO
HO
OH
Br
Pd(OAc)2, P(o-tolyl)3
Et3N, MeCN
OTMS

160


TMSO
HO
HO
TBAF
OTMS


161




162

Synthesis of 6-*O*-aryl propargyl azalide begins with a common intermediate, the TMS protected azithromycin 159, with similar coupling methodology applied in Scheme 8, providing product 165.


Scheme 8a. Synthesis of 6-O-Aryl Propargyl Azalide




159


HO
OH
TMSO
OCH3
OTMS
I
(Ph3P)2PdCl2, CuI
Et3N, CH3CN, 80°C

163


HO
HO
TMSO
OCH3
OTMS

164



165

The macrolide or ketolide can be formulated to provide a pharmaceutical composition useful in a method of treating TB. The macrolide or ketolide active agent, or a mixture of active agents, typically is present in such a pharmaceutical composition in an amount of about 0.1% to about 75% by weight.

Pharmaceutical compositions containing a macrolide or ketolide, i.e., the active agents, are suitable for administration to humans or other mammals. Typically, the pharmaceutical compositions are sterile, and contain no toxic, carcinogenic, or mutagenic compound which would cause an adverse reaction when administered.

A pharmaceutical composition containing an active agent or mixture thereof can be administered

by any suitable route, for example by oral, buccal, inhalation, sublingual, rectal, vaginal, intracisternal through lumbar puncture, transurethral, nasal, or parenteral (including intravenous, intramuscular, subcutaneous, and intracoronary) administration. A pharmaceutical composition containing the macrolide, ketolide, or mixture thereof preferably is administered by an oral or parenteral route. Parenteral administration can be accomplished using a needle and syringe. Implant pellets also can be used to administer an active agent parenterally. The active agents also can be administered as a component of an ophthalmic drug-delivery system.

The pharmaceutical compositions are administered in an effective amount to achieve its intended purpose. More specifically, a "therapeutically effective amount" means an amount effective to treat a disease. Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.

The exact formulation, route of administration, and dosage is determined by an individual physician in view of the patient's condition. Dosage amount and interval can be adjusted individually to provide levels of the active agents that are sufficient to maintain therapeutic or prophylactic effects.

The amount of pharmaceutical composition administered is dependent on the subject being treated, on the subject's weight, the severity of

the affliction, the manner of administration, and the judgment of the prescribing physician.

Specifically, for administration to a human in the curative or prophylactic treatment of a disease, oral dosages of an active agent is about 10 to about 500 mg daily for an average adult patient (70 kg). Thus, for a typical adult patient, individual doses contain about 0.1 to about 500 mg active agent, in a suitable pharmaceutically acceptable vehicle or carrier, for administration in single or multiple doses, once or several times per day. Dosages for intravenous, buccal, or sublingual administration typically are about 0.1 to about 10 mg/kg per single dose as required. In practice, the physician determines the actual dosing regimen that is most suitable for an individual patient and disease, and the dosage varies with the age, weight, and response of the particular patient. The above dosages are exemplary of the average case, but there can be individual instances in which higher or lower dosages are merited, and such are within the scope of this invention.

An active agent can be administered alone, or in admixture with a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice. Pharmaceutical compositions for use in accordance with the present invention, including ophthalmic preparations, thus can be formulated in a conventional manner using one or more physiologically acceptable carriers comprising excipients and auxil-

iaries that facilitate processing of an active agent into preparations that can be used pharmaceutically.

These pharmaceutical compositions can be manufactured in a conventional manner, e.g., by conventional mixing, dissolving, granulating, dragee-making, emulsifying, or lyophilizing processes. Proper formulation is dependent upon the route of administration chosen. When a therapeutically effective amount of an active agent is administered orally, the formulation typically is in the form of a tablet, capsule, powder, solution, or elixir. When administered in tablet form, the pharmaceutical composition additionally can contain a solid carrier, such as a gelatin or an adjuvant. The tablet, capsule, and powder contain about 5% to about 95%, preferably about 25% to about 90%, of an active agent of the present invention. When administered in liquid form, a liquid carrier, such as water, petroleum, or oils of animal or plant origin, can be added. The liquid form of the pharmaceutical composition can further contain physiological saline solution, dextrose or other saccharide solutions, or glycols. When administered in liquid form, the pharmaceutical composition contains about 0.5% to about 90%, by weight, of an active agent, and preferably about 1% to about 50%, by weight, of an active agent.

When a therapeutically effective amount of an active agent is administered by intravenous, cutaneous, or subcutaneous injection, the composition is in the form of a pyrogen-free, parenterally

acceptable aqueous preparation. The preparation of such parenterally acceptable solutions, having due regard to pH, isotonicity, stability, and the like, is within the skill in the art. A preferred composition for intravenous, cutaneous, or subcutaneous injection typically contains an isotonic vehicle in addition to an active agent of the present invention.

An active agent can be readily combined with pharmaceutically acceptable carriers well-known in the art. Such carriers enable the active agent to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated. Pharmaceutical compositions for oral use can be obtained by adding the active agent with a solid excipient, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients include, for example, fillers and cellulose preparations. If desired, disintegrating agents can be added.

An active agent can be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Compositions for injection can be presented in unit dosage form, e.g., in ampules or in multidose containers, with an added preservative. The compositions can take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and can contain formula-

tory agents such as suspending, stabilizing, and/or dispersing agents.

Pharmaceutical compositions for parenteral administration include aqueous dispersions of the active agent. Additionally, suspensions of the active agent can be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils or synthetic fatty acid esters. Aqueous injection suspensions can contain substances which increase the viscosity of the suspension. Optionally, the suspension also can contain suitable stabilizers or agents that increase the dispersibility of the compounds and allow for the preparation of highly concentrated compositions. Alternatively, a present pharmaceutical composition can be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

An active agent also can be formulated in rectal compositions, such as suppositories or retention enemas, e.g., containing conventional suppository bases. In addition to the preparations described previously, an active agent also can be formulated as a depot preparation. Such long-acting preparations can be administered by implantation (for example, subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, an active agent can be formulated with suitable polymeric or hydrophobic materials (for example, as an emulsion in an acceptable oil) or ion exchange resins.

In particular, an active agent can be administered orally, buccally, or sublingually in the form of tablets containing excipients, such as starch or lactose, or in capsules or ovules, either alone or in admixture with excipients, or in the form of elixirs or suspensions containing flavoring or coloring agents. Such liquid compositions can be prepared with pharmaceutically acceptable additives, such as suspending agents. A composition also can be injected parenterally, for example, intravenously, intramuscularly, subcutaneously, or intracoronarily. For parenteral administration, the composition is best used in the form of a sterile aqueous solution which can contain other substances, for example, salts, or monosaccharides, such as mannitol or glucose, to make the solution isotonic with blood.

For veterinary use, an active agent is administered as a suitably acceptable formulation in accordance with normal veterinary practice. The veterinarian can readily determine the dosing regimen and route of administration that is most appropriate for a particular animal.

The present invention, therefore, discloses the use of a macrolide, a ketolide, or mixtures thereof, for the oral, parenteral, sublingual, rectal, vaginal, or urethral treatment of TB. The method comprises administering a therapeutically effective amount of a pharmaceutical preparation comprising an active agent.


Various macrolides and ketolides were evaluated *in vitro* against *M. tuberculosis*. For example, RU60887, RU66252, RU69874, and A323348 demonstrated a minimum inhibitory concentration (MIC) against *M. tuberculosis* of 0.12, 0.25, 0.38, and 0.38 μM, respectively. The discovery of sub-micromolar anti-TB MICs, and a cytotoxicity comparable to clarithromycin, of the four compounds was unexpected, as was the observation of an SAR that appeared unique to *M. tuberculosis* compared to an SAR previously observed with *Staph* and *Strep*.

In addition, telithromycin, cethromycin (ABT-773), and twenty-eight additional compounds were tested. Although highly active against *Staph* and *Strep* that are resistant to second-generation macrolides, telithromycin is even less active than clarithromycin against *M. tuberculosis*, confirming the previous observation made by Rastogi et al. (2000) for various mycobacteria. Although the cethromycin MIC of 3 uM against *M. tuberculosis* is superior to other commercial macrolides, it is still above the C_{max}, i.e., the maximum blood concentration, for erythromycin.

As illustrated in the following Tables 1, 1a, 2, and 2a, modifications on positions 6, 9, 11 and 12 of erythromycin provided compounds having a potent anti-TB activity and a low toxicity.

Table 1. The11,12-Carbamate Derivatives Structures

Compound Structure















	R_2,	R_3,R_3'	R_6,	R_9	R_{11}
RU66080	H		Me	O	
RU66252	H		Me	O	
RU004	H	=O	Me	O	
RU3562	F	=O	Me	O	
RU69697	H	=O	Me	O	
RU69874	H		Me	O	
Telithromycin	H	=O	Me	O	
RU60856	H	=O	Me	O	
RU61143	H	=O	Me	O	

Table 1. The11,12-Carbamate Derivatives Structures

Compound Structure












	R_2,	R_3,R_3'	R_6,	R_9	R_{11}
RU63013	H	=O	Me	O	
RU66898	H	=O	Me	O	
RU62041	H	=O	Me	O	
RU62543	H	=O	Me	O	
RU60849	H	=O	Me	O	
RU70332	H	=O	Me	O	
RU70645	H	=O	Me	O	
RU61205	H	=O	Me	O	
RU66740	H	=O	Me	O	
A323348	F	=O		O	H
ABT773	H	=O		O	H
A192803	H	=O		O	H

Table 1a. Anti-TB Activity (MIC, μM) and Toxicity (IC_{50}, μM) of 11,12-Carbamate Derivatives

		Vero		J774	
Compound	MIC	IC_{50}	SI	IC_{50}	SI
RU66080	0.44	8.1	18.41	4.95	11.14
RU66252	0.25	24.93	99.72	16.13	64.52
RU004	4	26.34	6.58		
RU3562	16				
RU69697	4	7.32	1.83		
RU69874	0.38	26.96	70.95	58.59	154.18
Telithromycin	48			102.4	2.2
RU60856	4	>104.8	>26.2	102.4	25.6
RU61143	2	24.25	12.13	6	3
RU63013	3	7.37	2.46		
RU66898	3.3	6.93	2.1		
RU62041	1	8.19	8.19	13.3	7.6
RU62543	2.67	8.71	3.26		
RU60849	3	8.84	2.95		
RU70332	6	26.04	4.34		
RU70645	14				
RU61205	112				
RU66740	>128				
A323348	0.38	24.29	63.92	15.27	40.18
ABT773	3	>104.8	>34	102.4	34.1
A192803	>128				
RMP	0.076	46.7	614	32.66	430

Table 2. The 11,12-Diol Derivatives Structures








Compound	Structure		
			
	R_3,R_3'	R_6	R_9
RU60887	=O	Me	
RU61804	=O	Me	
ITR002	=O	Me	
ITR003	=O	Me	
RU54615	=O	Me	$NOCH_2O(CH_2)_2OCH_3$
RU29558		H	$NOCH_2OBn$
RU56006	=O	Me	O
Clarithromycin		Me	O

Table 2a. Anti-TB Activity (MIC, μM) and Toxicity (IC_{50}, μM) of the 11,12-Diols

		Vero		J774	
Compound	MIC	IC_{50}	SI	IC_{50}	SI
RU60887	0.125	27.58	220.64	4.7	37.6
RU61804	0.5	9.12	18.24	3.9	7.8
ITR002	64				
ITR003	128				
RU54615	>128				
RU29558	7	28.15	4.02		
RU56006	>128				
Clarithromycin	8	40.99	5.12		

The results summarized in Tables 1 and 2 illustrate some aspects of the anti-TB activity of macrolides. The most potent compound, RU60887, exhibited an MIC of 0.125 μM. It is envisioned that derivatives of RU60887 and other macrolides would provide more potent anti-TB compounds, for example, at least 10-fold or more potent MIC values vs. *M. tuberculosis*. Importantly, some of the most potent compounds also demonstrated a low toxicity. When VERO cells were used in a toxicity assay, RU60887 exhibited a selectivity index (SI) of 221. When more sensitive J774 cells were used, RU69874 displayed an SI of 154.

The data summarized in these tables show that in a comparison of three pairs of corresponding macrolides and ketolides, i.e., RU69874 and telithromycin, RU66252 and RU004, clarithromycin, and RU56006, each macrolide was significantly more potent than the counterpart ketolide. The enhancements in potency were 126, 16, and 16 fold, respectively. In addition, the macrolides not only exhibited an enhanced potencies over ketolides, but toxicities were not sacrificed to a significant degree. For example, when comparing (a) RU66252 to RU004 and (b) RU69874 to telithromycin, toxicity either was unchanged (25 μM vs. 26 μM, based on VERO cells) or changed insignificantly (59 μM vs. 102 μM, based on J774 cells). Accordingly, a macrolide is a preferred compound for use in the present method of treating TB.

Table 2 summarizes activities of the 9-oxime compounds. The two piperidine compounds, i.e., RU60887 and RU61804, are the most potent of the tested 9-oxime compounds. It was noted that a 9-oxime substitution alone did not provide potency, as shown from the results for RU54615.

Low dose aerosol model of acute infection.

Prior to assessing *in vivo* efficacy, RU66252 and RU69874 were administered to pairs of female Balb/C mice once daily for 5-day cycles, and observed for overt signs of toxicity (e.g., weight loss, ruffled fur, and huddling), after which the mice were rested for 1 or 2 days. Then the dosage was increased for another 5-day cycle. Overall, the same mice received sequentially for 5 days: 200, 300, 400, and 500 mg/kg. No signs of overt toxicity were noted throughout the study.

Female BALB/c mice were infected via aerosol with a low dose of *M. tuberculosis* Erdman. Mice were treated once daily by gavage from day 10-30 post-infection. RU66252 and RU69874 were assessed at both 100 and 200 mg/kg qd. RU60887 was produced in sufficient quantity to test at a single dosage--100 mg/kg qd. Untreated controls did not reach levels typically achieved (10^5-10^6/mouse) with colony counts of less than 10 on individual plates. Normal colony counts were obtained on treated mouse lung homogenates, and the results strongly suggest dose-dependent activity of RU66252 (no colonies on 10^{-2} dilution plates) against *M. tuberculosis* in the

acute phase of infection, with less activity noted for the other tested compounds.

***In vitro* activity and selectivity.**

The present compounds are tested for MIC against *M. tuberculosis* $H_{37}Rv$ in axenic medium and for cytotoxicity against VERO cells.

Cytotoxicity. Compounds are routinely tested for cytotoxicity in the ITR using VERO cells (C.L. Cantrell et al., *J. Nat. Prod.*, *59*:1131-36 (1996); G.C. Mangalindan et al., *Planta Med.*, *66*:364-5 (2000)). Macrolides are tested against VERO cells at concentrations less than or equal to 1% of the maximum achievable stock concentration. This results in a final DMSO concentration of less than or equal to 1% v/v, which is approximately the maximum non-cytotoxic concentration. Testing at very high concentrations allows for the recognition of high degrees of selectivity. Repeat testing is performed for compounds for which the IC_{50} is less than or equal to the lowest tested concentration, when this concentration also is above the MIC for *M. tuberculosis*. After 72 hours exposure, viability is assessed on the basis of cellular conversion of MTS into a soluble formazan product using the Promega CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay. Rifampin, clarithromycin, cethromycin, and telithromycin are included as controls.

For macrolides having an IC_{50}:MIC ratio greater than >10, cytotoxicity is repeated using the J774.1 macrophage cell line because these are used

in the macrophage assay and typically all more sensitive than VERO cells.

Macrophage assay. Compounds for which the IC_{50}:MIC (SI) ratio is greater than >10 are tested for killing of *M. tuberculosis* Erdman (ATCC 35801) in monolayers of J774.1 murine macrophages (EC_{99} and EC_{90}; lowest concentration effecting a 90% and 99% reduction in colony forming units at 7 days compared to drug-free controls) at 4-fold or 5-fold concentrations with the lowest concentration just below the MIC.

Description of Assays Demonstrating Whole-Cell Activity (MIC) against *M. tuberculosis*

MIC/MBC. Compounds are evaluated for MIC vs. *M. tuberculosis* $H_{37}Rv$ using the microplate Alamar Blue assay (MABA) described in (L. Collins et al., *Antimicrob. Agents Chemother., 41*:1004-9 (1997)) except that 7H12 media, rather than 7H9 + glycerol + casitone + OADC, is used. The use of this and other redox reagents, such as MTT, have shown excellent correlation with cfu-based and radiometric analyses of mycobacterial growth. The MIC is defined as the lowest concentration effecting a reduction in florescence (or luminescence) of 90% relative to controls. Isoniazid and rifampin are included as positive quality control compounds for each test, with expected MIC ranges of 0.025-0.1 and 0.06-0.125 ug/ml, respectively. MBCs are determined by subculture onto 7H11 agar just prior to addition of Alamar Blue and Tween 80 reagents to the test wells. The

MBC is defined as the lowest concentration reducing cfu BY 99% relative to the zero time inoculum.

Several additional compounds were synthesized by a parallel synthesis and tested for an ability to control *M. tuberculosis in vitro*. The compounds were prepared as follows.

1) 2',4"-Diacetyl Clarithromycin. The synthesis begins with acetyl protection on commercially available clarithromycin (Scheme 9). Clarithromycin (10 g, 13.4 mmol) was dissolved in anhydrous dichloromethane (48 mL) and cooled 0°C, followed by addition of triethylamine (5.2 mL, 37.4 mmol), DMAP (0.078 g, 0.67 mmol), and acetic anhydride (3.0 mL, 32.1 mmol). The reaction mixture was stirred at room temperature overnight.

Saturated aqueous ammonium chloride (40 mL) was added into the reaction mixture, which then was extracted with dichloromethane (2 x 40 mL). The aqueous phase was neutralized with saturated aqueous sodium hydrogen carbonate, and extracted with dichloromethane (2 x 40 mL). The combined organic phase was dried over sodium sulfate. Filtration of sodium sulfate followed by evaporation of solvent, afforded diacetylated clarithromycin 1 as white powder (11.09 g, 13.3 mmol, 100%). Selected ^{1}H NMR (δ, $CDCl_3$, 300 MHz) resonance: 2.10, 2.06.

2) Acyl Imidazole 2. Protected clarithromycin 1 (1.66 g, 2 mmol) was dissolved in anhydrous THF (17 mL), cooled to -40°C, followed by addition of 1M THF solution of NaHMDS (2.4 mL, 2.4 mmol), and stirred for 40 min.

In a separate round-bottomed flask, CDI (1.3 g, 8 mmol) was dissolved in THF/DMF mixture (12 mL/8 mL), and transferred into the solution of 1, and stirred for 24 h at room temperature.

Ethyl acetate was added into the reaction mixture, followed by 5% aqueous sodium hydrogencarbonate solution. After separation of the phases, the organic phase was washed with brine. Drying over sodium sulfate and concentration afforded acyl imidazole 2 as solid foam (1.50 g, 1.65 mmol, 83%). Selected ^{1}H NMR (δ, $CDCl_3$, 300 MHz) resonance: 8.08, 7.36, 7.07, and 6.66.

3) Clarithromycin Carbazate 3. The acyl imidazole 2 (3.63 g, 4 mmol) was dissolved in acetonitrile (40 mL), followed by addition of hydrazine (1.95 mL, 40 mmol) and water (4.35 mL). The reaction mixture was stirred for 6 h at 60°C.

After concentration, the reaction mixture was purified with flash chromatography, providing the desired carbazate 3 as white powder with quantitative yield. Selected ^{13}C NMR (δ, $CDCl_3$, 75 MHz) resonance: 217.5.

4) Library of 48 Functionalized Carbazates. Carbazate 3 (4.15 g, 50 mmol) was dissolved in anhydrous methanol (37.5 mL). This solution (0.75 mL, 0.1 mmol) was added into each of 48 reaction tubes in a Bohdan MiniBlock, followed by addition of 48 individual aldehydes in Chart 1, and glacial acetic acid (0.025 mL,0.4 mmol each). The reaction block was shaken on a vertex shaker for 20 h. Sodium cyanoboronhydride (0.2 mL, 0.2 mmol each


of 1 M THF solution) was added into individual reaction tube, shaken for 4 h.

The 48 reaction mixtures were purified with SPE with a second MiniBlock. The reaction mixtures were loaded on 48 C-18 SPE cartridges, followed by water wash, and eluted into 48 collection tubes with methanol. After drying in a SpeedVac, powdery desired library 4 was obtained.

5) Deacetylation. Library 4 was dissolved in methanol (2 mL each), followed by addition of 2 N sodium hydroxide (0.3 mL each), and shaken for 24 h.


The reaction mixtures were purified with SPE in a similar fashion, obtaining the desired library 5 (4-50 mg) as powders. The identity and purity were assessed with LC-MS.

Scheme 9



i = 1-48.

Chart 1.


A2
A4
A6
A8
A10
A12
B1
B3
B5
B7
B9
B11
C2
C4
C6
C8
C10
C12
D1
D3
D5
D7
D9
D11
E2
E4
E6
E8
E10
E12
F1
F3
F5
F7
F9
F11
G2
G4
G6
G8
G10
G12
H1
H3
H5
H7
H9
H11


The compounds demonstrated the following MICs:

Table 3. MIC		
Compound	Prod.FW	MIC, μM
A2'	906.2	10
A4'	904.1	7
A6'	980.2	10.2
A8'	913.1	>9
A10'	868.1	>7
A12'	940.1	>12
B1'	1050.7	>18
B3'	882.1	>18
B5'	882.1	>27
B7'	958.6	>19
B9'	944.2	>14
B11'	976.2	>22
C2'	1007.3	7
C4'	1071.3	11
C6'	897.1	>17
C8'	951.2	?9
C10'	959.2	12
C12'	959.2	9
D1'	947.0	23
D3'	984.5	20
D5'	962.2	25
D7'	976.2	13
D9'	879.1	>15
D11'	929.1	16
E2'	978.2	>27
E4'	978.2	>27
E6'	970.2	5
E8'	912.1	>20
E10'	920.1	20
E12'	977.6	3.4
F1'	1011.2	17.6
F3'	957.2	9
F5'	913.2	>19
F7'	935.2	16
F9'	961.2	12.6
F11'	963.0	12.7
G2'	934.2	11


Table 3. MIC		
Compound	Prod.FW	MIC, μM
G4'	976.2	13
G6'	932.1	11
G8'	1007.4	14
G10'	886.1	>16
G12'	1112.4	19
H1'	947.0	11
H3'	936.2	>22
H5'	920.1	>20
H7'	933.1	>22
H9'	984.6	?3
H11'	1066.8	35.4

Despite the complexion of the reaction products, F3' (the product from F3) is the desired product RU66252. Using RU66252 as a reference point, preferred compounds are shown in Chart 2.


Chart 2.



Mol. Wt.: 957.2
m/e: 956.6 (100.0%), 957.6 (59.9%), 958.6 (20.2%), 959.6 (5.0%)




Mol. Wt.: 982.6
m/e: 981.5 (100.0%), 982.5 (57.3%), 983.5 (50.9%), 984.5 (22.9%), 985.5 (6.9%), 986.5 (1.6%)




Mol. Wt.: 977.6
m/e: 976.5 (100.0%), 977.5 (58.8%), 978.5 (51.5%), 979.5 (23.5%), 980.5 (7.2%), 981.5 (1.7%)

Compound: **F3' (RU66252)** **H9'** **E12'**


MIC, μM: 9 3 3.4



Mol. Wt.: 968.2
m/e: 967.6 (100.0%), 968.6 (58.4%), 969.6 (20.4%), 970.6 (5.0%), 968.5 (1.9%)




Mol. Wt.: 904.1
m/e: 903.5 (100.0%), 904.5 (55.0%), 905.6 (14.9%), 906.6 (4.1%), 905.5 (3.2%), 904.6 (1.2%)




Mol. Wt.: 1007.3
m/e: 1006.6 (100.0%), 1007.6 (64.4%), 1008.6 (23.0%), 1009.6 (5.9%), 1010.6 (1.2%)

Compound: **E6'** **A4'** **C2'**

MIC, μM: 5 7 7



Mol. Wt.: 957.2
m/e: 956.5 (100.0%), 957.5 (58.8%), 958.5 (19.8%), 959.5 (4.9%)



Mol. Wt.: 949.2
m/e: 948.5 (100.0%), 949.5 (56.2%), 950.5 (22.7%), 951.5 (6.8%), 952.5 (1.7%)

Compound: **C12'** **C8'**

MIC, μM: 9 9

Modifications and variations of the invention as hereinbefore set forth can be made without departing from the spirit and scope thereof, and only such limitations should be imposed as are indicated by the appended claims.

WHAT IS CLAIMED IS:

1. A method of treating tuberculosis comprising administering a therapeutically effective amount of a macrolide, a ketolide, or a mixture thereof, to an individual in need thereof, wherein the macrolide or ketolide has an MIC vs. *M. tuberculosis* of about 50 μM or less.


2. The methodaim 1 wherein the macrolide or ketolide is disclosed in Table 1 of the specification.

3. The method of claim 1 wherein the macrolide or ketolide is disclosed in Chart 1 of the specification.


4. The method of claim 1 wherein the macrolide or ketolide is disclosed in Chart 2 of the specification.

5. The method of claim 1 wherein the macrolide or ketolide is selected from the group consisting of RU60887, RU66252, RU69874, RU60856, RU62041, RU61143, RU70332, A323348, and mixtures thereof.

6. The method of claim 1 wherein the macrolide or ketolide has a structural formula




wherein R^3 and $R^{3'}$ are taken together as =O, or $R^{3'}$ is H and R^3 is




;


R_6 is selected from the group consisting of: $-CH_2-CH=CH-R^a$ and $-CH_2C\equiv C-R^a$, wherein R^a is selected from the group consisting of:




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,



,




, and




;

R^9 is selected from the group consisting of:




and




,


wherein R^b is selected from the group consisting of C_{1-10} alkyl,



,



, and




;


and R^d is selected from the group consisting of H, $-CH_2-C\equiv CH$,



,




,




; and


R^{11} is selected from the group consisting of




,




,


O
NH2


,


Cl
NH2


,


OMe
N
NH2


,


N
MeO
NH2


,


HN
NH2


,


NH2


,




,





,





,



















,




,




,


and $-NHR^c$, wherein R^c is selected from the group consisting of


OMe
N
CH2-


,


N
MeO
CH2-


,


Cl
CH2-


,


CH2-


,


CN
CH2-


,


CN
CH2-


,


NO2
CH2-


,


NO2
O
-H2C


,


O2N
OH
CH2-


,


N
(CH2)3-


,




,




,




,




,




,


N
N
N
N
-(CH2)3


7. The method of claim 1 wherein the macrolide or ketolide has a structural formula




wherein R_f is selected from the group consisting of $-CH_2CH=CH-R_g$ and $-CH_2C\equiv C-R_g$, wherein R_g is selected from the group consisting of




,




,




,




,




,




,




,




,




,




,


N
S


,


N
S


,


N
S


,


N
S
N


,


N
S
N


,


N
S
CN


,


O
S


,


S
S
N


,




,




,




,



,




, and




.

8. The method of claim 1 wherein the macrolide or ketolide has a structural formula




wherein R is




m and n are individually integers from 0 to 6, A and B are individually a member selected from the group consisting of hydrogen, halogen, and alkyl of 1 to 8 carbon atoms, the double bond geometry being E or Z or E+Z or A and B for a third bond between the carbon atoms to which they are attached, Ar is selected from the group consisting of a) carbocyclic aryl or up to 18 carbon atoms optionally substituted with at least one member of the group consisting of free carboxy, alkoxycarbonyl, carboxy salified with a nontoxic, pharmaceutically acceptable base, amid-

ified carboxy, -OH, halogen, $-NO_2$, -CN, alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, alkynyloxy, alkylthio, alkenylthio, and alkynylthio of up to 12 carbon atoms, N-alkyl, N-alkenyl, and N-alkynyl of up to 12 carbon atoms and cycloalkyl of 3 to 12 carbon atoms, all optionally substituted with at least one halogen and



R_1 and R_2 are individually selected from the group consisting of hydrogen, alkyl of 1 to 12 carbon atoms, carbocyclic aryl, aryloxy, arylthio, heterocyclic aryl, and aryloxy and arylthio containing at least one heteroatom, all optionally substituted as above and b) heterocyclic aryl having at least one heteroatom optionally substituted with at least one of the above substituents, Z is hydrogen or acyl or an organic carboxylic acid of 1 to 18 carbon atoms and their nontoxic, pharmaceutically acceptable acid addition salts.

9. The method of claim 1 wherein the macrolide or ketolide has a structural formula



or a therapeutically acceptable salt or prodrug thereof, wherein

X is selected from hydrogen and fluoride;


D^1 is selected from CH=CH or C≡C;

Y^1 is selected from isoxazole, oxazole, isothiazole, dihydroisoxazole, and dihydrooxazole;


A^1 is selected from aryl and heteroaryl; and

R^1 is selected from hydrogen and R^p, wherein R^p is a hydroxyl protecting group.

10. The method of claim 1 wherein the macrolide or ketolide has a structural formula




wherein R and R_1 are -OH or -O-acyl of an organic carboxylic acid of 2 to 20 carbon atoms, R_2 is hydrogen or methyl, R_3 is $-(CH_2)_m-R_4$ or



or $-N-(CH_2)_q-R_4$, m is an integer from 1 to 6, a, p, and q are individually an integer from 0 to 6, A and B are individually selected from the group consisting of hydrogen, halogen, and alkyl of 1 to 8 carbon atoms with the geometry of the double bond being E or Z or a mixture of E and Z or A and B form a triple bond, R_4 is an optionally substituted mono- or polycyclic heterocycle and their nontoxic, pharmaceutically acceptable acid addition salts.


11. The method of claim 1 wherein the macrolide or ketolide has a structural formula



wherein X represents a CH_2 or SO_2 radical or an oxygen atom, Y represents a $(CH_2)_m(CH{=}CH)_n(CH_2)_o$ radical, with $m+n+o \leq 8$, n=0 or 1,

Ar represents an optionally substituted aryl radical, and


W represents a hydrogen atom, or the remainder of a carbamate function



wherein R" represents an alkyl radical containing up to 8 carbon atoms or an optionally substituted aryl radical,


Z represents a hydrogen atom or the remainder of an acid, as well as their addition salts with acids.

12. The method of claim 1 wherein the macrolide or ketolide has a structural formula




,

wherein X and Y are hydrogen or together form



,


R is



,

m is an integer from 0 to 20, n is 0, 1, 2, or 3, A and B are individually selected from the group consisting of hydrogen, halogen, alkyl of 1 to 8 carbon atoms and aryl of 6 to 8 carbon atoms with the double bond geometry being E or Z or a mixture of E

and Z or A and B form a third bond between the carbons to which they are attached, X_A is selected from the group consisting of alkyl, alkenyl, and alkynyl of 6 to 20 carbon atoms optionally interrupted with at least one heteroatom and optionally substituted with at least one halogen, cycloalkyl of 3 to 8 carbon atoms optionally substituted by a carbocyclic aryl, halogen, -CN, $-OR_3$, $-COR_4$, $-COOR_5$, $-SR_6$, $-SOR_7$, $-SO_2R_8$,



$-OC(Ar)_3$, and a carbocyclic aryl and heterocyclic aryl optionally substituted, R_3, R_4, R_5, R_6, R_7, R_8, and R_9 are individually selected from the group consisting of hydrogen, alkyl of 1 to 8 carbon atoms optionally interrupted by at least one heteroatom and optionally substituted by at least one halogen, carbocyclic, and heterocyclic aryl and aralkyl of up to 14 carbon atoms optionally substituted with at least one member of the group consisting of free, salified, esterified, or amidified carboxy, -OH, halogen, $-NO_2$, -CN, alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, alkynyloxy, alkylthio, alkenylthio, alkynylthio, -SO-alkyl, -SO-alkenyl, -SO-alkynyl, $-SO_2$-alkyl, $-SO_2$alkenyl, and $-S_2$-alkynyl of up to 12 carbon atoms, all optionally substituted with at least one halogen, carbocyclic, and heterocyclic, aryl, O-aryl, and -S-aryl of up to 14 carbon atoms,

R'_1 and R'_2 are individually selected from the group consisting of hydrogen and alkyl of 1 to 12 carbon atoms, R_1 and R_2 are individually selected from the group consisting of hydrogen, alkyl of 1 to 20 carbon atoms, -COAlk, and -COO-Alk, aryl, -CO-aryl, -COO-aryl, aralkyl, -CO-aralkyl, and -COO-aralkyl of up to 14 carbon atoms, Alk of alkyl of 1 to 8 carbon atoms, or R_1 and R_2 together with the nitrogen to which they are attached form ring of 3 to 8 members optionally containing a second heteroatom and optionally substituted with the above aryl substituents, Ar is a carbocyclic aryl optionally substituted with at least one of the above aryl substituents, Z is hydrogen or aryl of an organic carboxylic acid of up to 18 carbon atoms and their nontoxic, pharmaceutically acid addition salts.

13. The method of claim 1 when the macrolide or ketolide comprises a macrolide.

14. The method of claim 1 wherein the tuberculoses comprises latent tuberculosis, active tuberculosis, or multidrug-resistant tuberculosis.

15. The method of claim 1 further comprising administering a therapeutically effective amount of a second drug useful in treatment of tuberculosis.

16. The method of claim 15 wherein the second drug is selected from the group consisting of isoniazid, rifampin, pyrazinamide, streptomycin, and mixtures thereof.

17. The method of claim 15 when the macrolide or ketolide and the second drug are administered simultaneously.

18. The method of claim 15 when the macrolide or ketolide and the second drug are administered sequentially.

19. An article of manufacture comprising:

(a) a packaged composition comprising a macrolide, ketolide, or mixture thereof;

(b) an insert providing instructions for administration of the packaged composition of (a) to treat tuberculosis; and

(c) a container for (a) and (b).

20. An article of manufacture comprising:

(a) a packaged composition comprising a macrolide, ketolide, or mixture thereof;

(b) a packaged composition comprising a second therapeutic agent useful in a treatment of tuberculosis;

(c) an insert providing instructions for a simultaneous or sequential administration of (a) and (b) to treat tuberculosis; and

(d) a container for (a), (b), and (c).

21. A compound selected from the group consisting of a compound disclosed in Table 1 of the specification and a compound disclosed in Table 3 of the specification.